Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Beyond the Protein: Manipulating Proteoforms with Chemical Tools

Project description

Targeting specific protein forms within cells

Although we have about 20 000 protein-coding genes, the human body can produce more than one protein variation from each gene. The diversity of proteins present in the human body increases through complex processes such as alternative mRNA splicing and post-translational modifications. Given that changes in specific proteins have been associated with cancer and neurogenerative diseases, it is crucial to understand the underlying mechanisms. The ERC-funded PROTEOFORMER project aims to develop chemical tools that can precisely manipulate selected protein forms inside cells. The project focuses on a brain receptor implicated in Parkinson’s disease and a key regulator of neuroinflammation. By adding functional chemical cargo directly to chosen protein forms, researchers will selectively inhibit or switch between protein forms.

Objective

The human body can synthesize ~70’000 different proteins. These proteins diversify into millions of proteoforms, e.g. by associating into complexes or acquiring functionalities called post-translational modifications (PTMs). Distinct proteoforms are often found in different cell types and have diverse functions. Dysregulation of specific proteoforms is associated with many diseases, including neurodegeneration or cancers, highlighting the need for their study and modulation. Despite these needs, most drug-like molecules are designed to indiscriminately activate, inhibit, or destroy a target protein—they are blind to the localization or function of different proteoforms.
PROTEOFORMER goes beyond the protein by developing chemical tools for manipulating specific protein forms. In two parallel initiatives, PROTEOFORMER will:
(1) Target a specific proteoform of the muscarinic acetylcholine receptor—relevant to Parkinson’s disease treatment—dissecting its function and laying the groundwork for new therapies.
(2) Modify post-translational modifications of matrix metalloproteinase-2—a key regulator of neuroinflammation—aiming to unravel their so-far-elusive function.
PROTEOFORMER offers tailored reagents that (i) recognize the protein target, (ii) bring a reactive group to the target’s surface, and (iii) attach molecular cargo to the protein via a proximity-induced reaction. It rethinks this ‘ligand-directed chemistry’ by introducing functional, proteoform-manipulating cargo:
(1) A blocker of a partner protein, enabling proteoform-selective inhibition within a cell-specific complex.
(2) A post-translational modification or its eraser, enabling on-demand switching between proteoforms with newly developed proximity-driven chemical reactions.
PROTEOFORMER develops new chemistry for manipulating proteoforms beyond current capabilities. These general concepts represent a chemical solution to long-standing challenges in biology that are intractable with traditional methods.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

Masarykova univerzita
Net EU contribution
€ 1 810 000,00
Address
Zerotinovo namesti 9
601 77 Brno
Czechia
Region
Česko Jihovýchod Jihomoravský kraj
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 810 000,00

Beneficiaries (1)